Abstract
Ensifentrine (RPL554), an inhaled 'bifunctional' dual phosphodiesterase 3/4 inhibitor that exhibits both bronchodilator and anti-inflammatory activities, provides a new option in the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases that are under clinical development. Ensifentrine appears to be initially under development for the treatment of COPD although it is not yet clear whether it should be understood as an add-on therapy in patients for the treatment of acute exacerbations of COPD or for the regular maintenance treatment of patients either alone, or on top of existing drug classes.
| Original language | English |
|---|---|
| Pages (from-to) | 249-257 |
| Number of pages | 9 |
| Journal | Pharmaceutical patent analyst |
| Volume | 7 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 18 Jan 2019 |
Keywords
- asthma
- COPD
- cystic fibrosis
- ensifentrine
- mixed phosphodiesterase (PDE)3/4 inhibitor
- PDE isoenzymes
